Gene info: ID 5144

Gene: PDE4D

GENE ID: 5144

Description: phosphodiesterase 4D

Gene type: protein-coding

Location: 5q11.2-q12.1

dbXrefs: Ensembl:ENSG00000113448 MIM:600129 Vega:OTTHUMG00000162218 UniprotKB:Q08499

RefSeq: NG_027957.1

Retrived from: PubMed|SNP Mapped

SNPs: 1 ANCO-SNPs

Phenotype: ND

# Publications: 14

Sherlock p-value : NA (AD) NA (ND) (Frontal_Cortex)

Pascal p-value : 9.424e-1 (AD) 6.687e-1 (ND)

ANCO-SNPs

SNP ID	Position	Alleles	Trait	Variation Type
rs17780175	chr5:59293960 (GRCh38.p7)	G>A	nicotine dependence	SNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
XPR1	0.896
FBXO28	0.887
KPNA1	0.885
GFPT1	0.88
SHOC2	0.877
RLIM	0.874
MOB4	0.874
PPP2R5E	0.871
RNGTT	0.868
HSPA13	0.868

Top 10 negatively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
OR4F5	-0.48
OR4F29	-0.429
TRPV5	-0.386
CTNNA3	-0.376
C5orf64	-0.376
CSAG1	-0.352
FXYD4	-0.345
TNFRSF13B	-0.341
SH2D1A	-0.335
ANXA13	-0.334

ID	Drug Name	Drug Type	CAS Num	Status	Role
DB00131	Adenosine monophosphate	Small Molecule	61-19-8	Approved\|Investigational\|Nutraceutical	Target
DB00651	Dyphylline	Small Molecule	479-18-5	Approved	Target
DB01088	Iloprost	Small Molecule	78919-13-8	Approved\|Investigational	Target
DB01656	Roflumilast	Small Molecule	162401-32-3	Approved	Target
DB01791	Piclamilast	Small Molecule	144035-83-6	Experimental	Target
DB01954	Rolipram	Small Molecule	61413-54-5	Investigational	Target
DB01959	3,5-Dimethyl-1-(3-Nitrophenyl)-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester	Small Molecule		Experimental	Target
DB02676	2-[3-(2-Hydroxy-1,1-Dihydroxymethyl-Ethylamino)-Propylamino]-2-Hydroxymethyl-Propane-1,3-Diol	Small Molecule		Experimental	Target
DB02918	6-(4-Difluoromethoxy-3-Methoxy-Phenyl)-2h-Pyridazin-3-One	Small Molecule		Experimental	Target
DB03183	1-(4-Aminophenyl)-3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester	Small Molecule		Experimental	Target
DB03606	(S)-Rolipram	Small Molecule	85416-73-5	Experimental	Target
DB03849	Cilomilast	Small Molecule	153259-65-5	Investigational	Target
DB04149	(R)-Rolipram	Small Molecule	85416-75-7	Experimental	Target
DB04271	3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester	Small Molecule		Experimental	Target
DB04469	1-(4-Methoxyphenyl)-3,5-Dimethyl-1h-Pyrazole-4-Carboxylic Acid Ethyl Ester	Small Molecule		Experimental	Target
DB05219	Crisaborole	Small Molecule	906673-24-3	Approved\|Investigational	Target
DB05266	Ibudilast	Small Molecule	50847-11-5	Approved\|Investigational	Target
DB05298	Tetomilast	Small Molecule	145739-56-6	Investigational	Target
DB05676	Apremilast	Small Molecule	608141-41-9	Approved\|Investigational	Target
DB06246	Exisulind	Small Molecule	59973-80-7	Investigational	Target
DB06842	(4R)-4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one	Small Molecule		Experimental	Target
DB07051	3,5-DIMETHYL-1-PHENYL-1H-PYRAZOLE-4-CARBOXYLIC ACID ETHYL ESTER	Small Molecule		Experimental	Target
DB07954	3-isobutyl-1-methyl-7H-xanthine	Small Molecule	28822-58-4	Experimental	Target
DB08299	4-[8-(3-nitrophenyl)-1,7-naphthyridin-6-yl]benzoic acid	Small Molecule		Experimental	Target
DB00201	Caffeine	Small Molecule	58-08-2	Approved	Target
DB09283	Trapidil	Small Molecule	15421-84-8	Approved	Target

ID	Drug Name	Action	PubMed
C554440	1-((5-(1-aminoethyl)-2-(8-methoxy-2-(triflurormethyl)-5-quinolinyl)-4-oxazolyl) carbonyl)-4-((cyclopropylcarbonyl)amino)proline ethyl ester	1-((5-(1-aminoethyl)-2-(8-methoxy-2-(triflurormethyl)-5-quinolinyl)-4-oxazolyl) carbonyl)-4-((cyclopropylcarbonyl)amino)proline ethyl ester results in decreased activity of PDE4D protein	20621091
C009505	4,4'-diaminodiphenylmethane	"4,4'-diaminodiphenylmethane results in decreased expression of PDE4D mRNA"	18648102
C583074	4,4'-hexafluorisopropylidene diphenol	"4,4'-hexafluorisopropylidene diphenol results in increased expression of PDE4D mRNA"	27567155
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE4D mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE4D mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE4D mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE4D mRNA"	27188386
C459179	4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE4D mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE4D mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE4D mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE4D mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE4D mRNA"	27188386
C516138	(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine	"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE4D mRNA"	27188386
D000082	Acetaminophen	Acetaminophen results in decreased expression of PDE4D mRNA	26690555
D016604	Aflatoxin B1	Aflatoxin B1 results in decreased methylation of PDE4D gene	27153756
D016604	Aflatoxin B1	Aflatoxin B1 results in decreased expression of PDE4D mRNA	19770486
D001151	Arsenic	Arsenic affects the methylation of PDE4D gene	25304211
C006632	arsenic trioxide	arsenic trioxide results in increased expression of PDE4D mRNA	22521957
D017638	Asbestos, Crocidolite	"Asbestos, Crocidolite affects the expression of PDE4D mRNA"	25757056
D001280	Atrazine	Atrazine results in increased expression of PDE4D mRNA	18461179
D001554	Benzene	Benzene results in increased expression of PDE4D mRNA	15929907
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in decreased expression of PDE4D mRNA	22316170
D015123	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of PDE4D mRNA"	19150397
D004958	Estradiol	Estradiol affects the expression of PDE4D mRNA	23557687
D004958	Estradiol	Estradiol results in decreased methylation of PDE4D gene	16740699
D004958	Estradiol	Estradiol results in increased expression of PDE4D mRNA	16740699
C006780	bisphenol A	bisphenol A results in decreased expression of PDE4D mRNA	25181051
C006780	bisphenol A	bisphenol A results in decreased methylation of PDE4D gene	16740699
C006780	bisphenol A	bisphenol A results in decreased methylation of PDE4D promoter	22109888
C006780	bisphenol A	[bisphenol A results in decreased methylation of PDE4D promoter] which results in increased expression of PDE4D	22109888
C006780	bisphenol A	bisphenol A results in increased expression of PDE4D mRNA	16740699
C006780	bisphenol A	bisphenol A results in increased methylation of PDE4D gene	28505145
C013418	bromfenacoum	bromfenacoum results in decreased expression of PDE4D protein	28903499
C018475	butyraldehyde	butyraldehyde results in decreased expression of PDE4D mRNA	26079696
D000074262	Canola Oil	Canola Oil metabolite results in decreased expression of PDE4D mRNA	27363782
D002713	Chlorine	[Ozone co-treated with Chlorine] results in increased expression of PDE4D mRNA	18636392
C074702	chromium hexavalent ion	chromium hexavalent ion results in decreased expression of PDE4D mRNA	27793765
C418118	CI 1044	CI 1044 results in increased expression of PDE4D mRNA	17569694
C433247	Cilomilast	Cilomilast results in decreased activity of PDE4D protein	11907180
C433247	Cilomilast	Cilomilast results in decreased expression of PDE4D mRNA	16956605
C433247	Cilomilast	Cilomilast results in decreased activity of PDE4D protein	17155857
C018021	cobaltous chloride	cobaltous chloride results in increased expression of PDE4D mRNA	19376846
D005576	Colforsin	Colforsin results in increased expression of PDE4D mRNA	15967414
D019327	Copper Sulfate	Copper Sulfate results in increased expression of PDE4D mRNA	19549813
D003471	Cuprizone	Cuprizone affects the expression of PDE4D mRNA	26577399
D003907	Dexamethasone	Dexamethasone inhibits the reaction [RX3 gene mutant form affects the expression of PDE4D mRNA]	27941970
D003999	Dichloroacetic Acid	Dichloroacetic Acid results in increased expression of PDE4D mRNA	28962523
D002945	Cisplatin	[Cisplatin co-treated with jinfukang] results in decreased expression of PDE4D mRNA	27392435
D002945	Cisplatin	Cisplatin results in decreased expression of PDE4D mRNA	27392435
C036042	dicyclohexyl phthalate	dicyclohexyl phthalate affects the expression of PDE4D mRNA	26924002
D004041	Dietary Fats	[Dietary Fats co-treated with resveratrol] results in increased expression of PDE4D mRNA	21852083
C024629	dimethyl phthalate	dimethyl phthalate affects the expression of PDE4D mRNA	26924002
D004137	Dinitrochlorobenzene	Dinitrochlorobenzene results in increased expression of PDE4D mRNA	17374397
C010452	estradiol-17 beta-benzoate	estradiol-17 beta-benzoate results in decreased methylation of PDE4D promoter	22109888
C010452	estradiol-17 beta-benzoate	[estradiol-17 beta-benzoate results in decreased methylation of PDE4D promoter] which results in increased expression of PDE4D	22109888
D000431	Ethanol	Ethanol results in decreased expression of PDE4D mRNA	20655511
D004997	Ethinyl Estradiol	Ethinyl Estradiol results in increased expression of PDE4D mRNA	29097150
D005473	Fluoxetine	Fluoxetine affects the expression of PDE4D mRNA alternative form	12504921
D005557	Formaldehyde	Formaldehyde results in decreased expression of PDE4D mRNA	20655997
C069837	fullerene C60	fullerene C60 results in decreased expression of PDE4D mRNA	19167457
C508665	gold (III) porphyrin 1a	gold (III) porphyrin 1a results in increased expression of PDE4D mRNA	16206274
D017313	Fenretinide	Fenretinide results in increased expression of PDE4D mRNA	28973697
D006820	Hyaluronic Acid	Hyaluronic Acid analog results in decreased expression of PDE4D protein	23178681
D006861	Hydrogen Peroxide	Hydrogen Peroxide results in decreased expression of PDE4D protein	23178681
D015759	Ionomycin	[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of PDE4D mRNA	25613284
C544151	jinfukang	[Cisplatin co-treated with jinfukang] results in decreased expression of PDE4D mRNA	27392435
C544151	jinfukang	jinfukang results in decreased expression of PDE4D mRNA	27392435
C561695	(+)-JQ1 compound	(+)-JQ1 compound results in decreased expression of PDE4D mRNA	27432991
C459562	L-826,141	"L-826,141 results in decreased activity of PDE4D protein"	15901792
C045463	leflunomide	leflunomide results in increased expression of PDE4D mRNA	28988120
C042720	mercuric bromide	mercuric bromide results in increased expression of PDE4D mRNA	26272509
C042720	mercuric bromide	"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE4D mRNA"	27188386
D008694	Methamphetamine	PDE4D gene SNP affects the susceptibility to Methamphetamine	18316681
C004925	methylmercuric chloride	methylmercuric chloride results in increased expression of PDE4D mRNA	28001369
D018817	N-Methyl-3,4-methylenedioxyamphetamine	"N-Methyl-3,4-methylenedioxyamphetamine results in decreased expression of PDE4D mRNA"	26251327
D008942	Mitoxantrone	PDE4D protein affects the susceptibility to Mitoxantrone	16217747
C016599	mono-(2-ethylhexyl)phthalate	mono-(2-ethylhexyl)phthalate results in decreased expression of PDE4D mRNA	22401849
C517284	monomethyl phthalate	monomethyl phthalate affects the expression of PDE4D mRNA	26924002
C568020	moracin M	moracin M binds to and results in decreased activity of PDE4D protein	23871879
D037742	Nanotubes, Carbon	"Nanotubes, Carbon results in decreased expression of PDE4D mRNA"	25511174
D037742	Nanotubes, Carbon	"Nanotubes, Carbon analog results in decreased expression of PDE4D mRNA"	25554681
C028007	nickel monoxide	nickel monoxide results in increased expression of PDE4D mRNA	19167457
C029938	nickel sulfate	nickel sulfate results in increased expression of PDE4D mRNA	17374397
C451724	NVP ABE171	NVP ABE171 results in decreased activity of PDE4D protein	11907180
D010081	Oxazolone	Oxazolone results in increased expression of PDE4D mRNA	17374397
D010126	Ozone	[Ozone co-treated with Chlorine] results in increased expression of PDE4D mRNA	18636392
C496932	panobinostat	"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE4D mRNA"	27188386
C496932	panobinostat	panobinostat results in increased expression of PDE4D mRNA	26272509
C568608	PCI 5002	[PCI 5002 co-treated with Zinc] results in increased expression of PDE4D mRNA	18593933
C046012	pentanal	pentanal results in decreased expression of PDE4D mRNA	26079696
D010662	Phenylmercuric Acetate	"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE4D mRNA"	27188386
D010662	Phenylmercuric Acetate	Phenylmercuric Acetate results in increased expression of PDE4D mRNA	26272509
D010852	Picrotoxin	Picrotoxin results in increased expression of PDE4D mRNA	15170462
C006253	pirinixic acid	pirinixic acid results in increased expression of PDE4D mRNA	18301758\|2081375
D011192	Potassium Dichromate	Potassium Dichromate results in increased expression of PDE4D mRNA	11678601
D011285	Pregnenolone Carbonitrile	Pregnenolone Carbonitrile results in decreased expression of PDE4D mRNA	28903501
C107773	pterostilbene	pterostilbene binds to PDE4D protein	23871879
C034912	puag-haad	puag-haad binds to PDE4D protein	23871879
D011794	Quercetin	Quercetin results in decreased activity of PDE4D protein	23873842
D020849	Raloxifene Hydrochloride	Raloxifene Hydrochloride results in increased expression of PDE4D mRNA	16497877
C059514	resveratrol	[Dietary Fats co-treated with resveratrol] results in increased expression of PDE4D mRNA	21852083
C059514	resveratrol	resveratrol analog binds to PDE4D protein	23871879
C059514	resveratrol	resveratrol binds to and results in decreased activity of PDE4D protein	23871879
D012293	Rifampin	Rifampin results in decreased expression of PDE4D mRNA	24552687
C424423	Roflumilast	Roflumilast results in decreased activity of PDE4D protein	15901792
C424423	Roflumilast	Roflumilast binds to PDE4D protein	23871879
D020889	Rolipram	Rolipram results in decreased activity of PDE4D protein	23873842
C017947	sodium arsenite	sodium arsenite affects the methylation of PDE4D gene	28589171
D012969	Sodium Fluoride	Sodium Fluoride results in increased expression of PDE4D mRNA	21340527
C004648	testosterone enanthate	testosterone enanthate results in increased expression of PDE4D mRNA	25603467
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in decreased expression of PDE4D mRNA	20106945\|2163298
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the expression of PDE4D mRNA	21570461
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the expression of PDE4D mRNA	22298810
D013750	Tetrachloroethylene	Tetrachloroethylene results in increased expression of PDE4D mRNA	28973375
D013755	Tetradecanoylphorbol Acetate	[Tetradecanoylphorbol Acetate co-treated with Ionomycin] results in decreased expression of PDE4D mRNA	25613284
C009495	titanium dioxide	titanium dioxide results in increased expression of PDE4D mRNA	23557971
D014028	Tobacco Smoke Pollution	Tobacco Smoke Pollution results in decreased expression of PDE4D mRNA	28065790
C483909	torcetrapib	torcetrapib results in increased expression of PDE4D mRNA	23228038
C035964	trequinsin	trequinsin results in decreased activity of PDE4D protein	15901792
D014212	Tretinoin	Tretinoin results in increased expression of PDE4D mRNA	21934132\|2372400
D014241	Trichloroethylene	Trichloroethylene results in increased expression of PDE4D mRNA	25549359
D014241	Trichloroethylene	Trichloroethylene results in increased methylation of PDE4D gene	27618143
C012589	trichostatin A	"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE4D mRNA"	27188386
C012589	trichostatin A	trichostatin A results in increased expression of PDE4D mRNA	24935251\|2627250
D014415	Tunicamycin	Tunicamycin results in increased expression of PDE4D mRNA	17127020
D014635	Valproic Acid	"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDE4D mRNA"	27188386
D014635	Valproic Acid	Valproic Acid affects the expression of PDE4D mRNA	25979313
D014635	Valproic Acid	Valproic Acid results in increased expression of PDE4D mRNA	23179753\|2438349
D000069470	Venlafaxine Hydrochloride	Venlafaxine Hydrochloride results in increased expression of PDE4D mRNA	25423262
C029297	vinylidene chloride	vinylidene chloride results in decreased expression of PDE4D mRNA	26682919
C111237	vorinostat	vorinostat results in increased expression of PDE4D mRNA	27188386
D015032	Zinc	[PCI 5002 co-treated with Zinc] results in increased expression of PDE4D mRNA	18593933

GO/Pathway

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0004114	3',5'-cyclic-nucleotide phosphodiesterase activity	-	NAS	10913353
GO:0004115	3',5'-cyclic-AMP phosphodiesterase activity	-	IDA	9371713 17404263
GO:0004115	3',5'-cyclic-AMP phosphodiesterase activity	-	IGI	8413254
GO:0004115	3',5'-cyclic-AMP phosphodiesterase activity	-	TAS	-
GO:0005515	protein binding	-	IPI	17620599 19955404 25416956
GO:0008144	drug binding	-	IPI	9371713 15938621
GO:0019899	enzyme binding	-	ISS	22975349
GO:0030552	cAMP binding	-	IDA	9371713 15938621
GO:0031698	beta-2 adrenergic receptor binding	-	ISS	-
GO:0044325	ion channel binding	-	IPI	16213210
GO:0044325	ion channel binding	-	ISS	-
GO:0046872	metal ion binding	-	IEA	-
GO:0051117	ATPase binding	-	IPI	21903937
GO:0097110	scaffold protein binding	-	IPI	15182229

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0002027	regulation of heart rate	-	ISS	16213210
GO:0006198	cAMP catabolic process	-	IEA	-
GO:0006198	cAMP catabolic process	-	IMP	19252089
GO:0006939	smooth muscle contraction	-	IEA	-
GO:0007186	G-protein coupled receptor signaling pathway	-	TAS	-
GO:0007568	aging	-	IEA	-
GO:0010469	regulation of signaling receptor activity	-	ISS	-
GO:0010880	regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum	-	ISS	16213210
GO:0019933	cAMP-mediated signaling	-	NAS	16177794
GO:0030593	neutrophil chemotaxis	-	IEA	-
GO:0032729	positive regulation of interferon-gamma production	-	IMP	17404263
GO:0032743	positive regulation of interleukin-2 production	-	IMP	17404263
GO:0032754	positive regulation of interleukin-5 production	-	IMP	17404263
GO:0033137	negative regulation of peptidyl-serine phosphorylation	-	ISS	16213210
GO:0035264	multicellular organism growth	-	IEA	-
GO:0045822	negative regulation of heart contraction	-	ISS	21903937
GO:0050852	T cell receptor signaling pathway	-	IMP	17404263
GO:0060314	regulation of ryanodine-sensitive calcium-release channel activity	-	ISS	16213210
GO:0061028	establishment of endothelial barrier	-	ISS	-
GO:0071222	cellular response to lipopolysaccharide	-	IEA	-
GO:0071872	cellular response to epinephrine stimulus	-	IEA	-
GO:0071875	adrenergic receptor signaling pathway	-	ISS	-
GO:0086004	regulation of cardiac muscle cell contraction	-	ISS	21903937
GO:0086024	adenylate cyclase-activating adrenergic receptor signaling pathway involved in positive regulation of heart rate	-	IC	-
GO:1901844	regulation of cell communication by electrical coupling involved in cardiac conduction	-	IC	16213210
GO:1901898	negative regulation of relaxation of cardiac muscle	-	ISS	-

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0005813	centrosome	-	IEA	-
GO:0005829	cytosol	-	IDA	-
GO:0005829	cytosol	-	TAS	-
GO:0005886	plasma membrane	-	IDA	-
GO:0005891	voltage-gated calcium channel complex	-	ISS	-
GO:0016324	apical plasma membrane	-	IEA	-
GO:0031965	nuclear membrane	-	IDA	-
GO:0034704	calcium channel complex	-	IDA	16213210

KEGG ID	KEGG Term
hsa00230	Purine metabolism

Reactome ID	Reactome Term	Evidence
R-HSA-111885	Opioid Signalling	TAS
R-HSA-162582	Signal Transduction	TAS
R-HSA-180024	DARPP-32 events	TAS
R-HSA-372790	Signaling by GPCR	TAS
R-HSA-388396	GPCR downstream signalling	TAS
R-HSA-418555	G alpha (s) signalling events	TAS
R-HSA-418594	G alpha (i) signalling events	TAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID	Title (Year)	Author	Journal
28191858	Impact of the PDE4D gene polymorphism and additional SNP-SNP and gene-smoking interaction on ischemic stroke risk in Chinese Han population. (2017 Apr)	Wang X	Neurol Res
12791581	Prenatal cigarette smoke decreases lung cAMP and increases airway hyperresponsiveness. (2003 Aug 1)	Singh SP	Am J Respir Crit Care Med
18398440	Ischaemic stroke in hypertensive patients is associated with variations in the PDE4D genome region. (2008 Sep)	Lovkvist H	Eur J Hum Genet
22274584	A large-sample assessment of possible association between ischaemic stroke and rs12188950 in the PDE4D gene. (2012 Jul)	Lovkvist H	Eur J Hum Genet
19608201	Phosphodiesterase 4D (PDE4D) gene variants and the risk of ischemic stroke in a South Indian population. (2009 Oct 15)	Munshi A	J Neurol Sci
27709636	PTTG1IP and MAML3, novel genomewide association study genes for severity of hyperresponsiveness in adult asthma. (2017 May)	Nieuwenhuis MA	Allergy
19399275	Phosphodiesterase 4D gene and risk of noncardiogenic ischemic stroke in a Korean population. (2009 Apr)	Kim MK	J Korean Med Sci
21989204	Association of the phosphodiesterase 4D (PDE4D) gene and cardioembolic stroke in an Australian cohort. (2011 Dec)	Milton AG	Int J Stroke
20008879	Genome-wide association studies: what do they teach us about asthma and chronic obstructive pulmonary disease? (2009 Dec)	Boezen HM	Proc Am Thorac Soc
27058054	Asthma susceptibility variants are more strongly associated with clinically similar subgroups. (2016 Nov)	Lavoie-Charland E	J Asthma
16825591	Polymorphisms of the phosphodiesterase 4D, cAMP-specific (PDE4D) gene and risk of ischemic stroke: a prospective, nested case-control evaluation. (2006 Aug)	Zee RY	Stroke
23193110	RGS5 gene and therapeutic response to short acting bronchodilators in paediatric asthma patients. (2013 Oct)	Labuda M	Pediatr Pulmonol
18157711	Association between inflammatory gene polymorphisms and coronary artery disease in an Indian population. (2009 Jan)	Banerjee I	J Thromb Thrombolysis
28027554	Features of coronary heart disease development in emergency workers of the Chornobyl accident depending on the action of radiation and non radiation risk factors and genotypes of single nucleotide polymorphism rs966221 of phosphodiesterase 4D gene. (2016 Dec)	Belyi D	Probl Radiac Med Radiobiol